Multicenter Study

. 2015 Dec;19(12):1524-7.

doi: 10.5588/ijtld.15.0274.

Beyond multidrug-resistant tuberculosis in Europe: a TBNET study

G Günther¹, F van Leth², N Altet³, M Dedicoat⁴, R Duarte⁵, G Gualano⁶, H Kunst⁷, I Muylle⁸, V Spinu⁹, S Tiberi¹⁰, P Viiklepp¹¹, C Lange¹²; TBNET

Collaborators, Affiliations

Collaborators

Affiliations

¹ Division of Clinical Infectious Diseases and German Center for Infection Research Tuberculosis Unit, Research Center Borstel, Borstel, Germany; Department of Medicine, University of Namibia School of Medicine, Windhoek, Namibia.
² Department of Global Health, Academic Medical Center, University of Amsterdam and Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands.
³ Hospital Universitari Vall d'Hebron, Barcelona, Spain; Investigació i Recerca en Atenció Primària Jordi Gol, Barcelona, Spain.
⁴ Heart of England Foundation Trust, Birmingham, UK.
⁵ Centro Hospitalar de Vila Nova Gaia/Espinho, Vila Nova Gaia, Portugal; EpiUnit, Institute of Public Health, Medical School Porto University, Porto, Portugal.
⁶ L Spallanzani National Institute for Infectious Diseases, Rome, Italy.
⁷ Heart of England Foundation Trust, Birmingham, UK; Queen Mary University, London, UK.
⁸ St Pieter University Medical Centre, Brussels, Belgium.
⁹ Marius-Nasta-Institut, Bucharest, Romania.
¹⁰ Azienda Ospedaliera di Valtellina e Valchiavenna E Morelli Hospital, Reference Hospital for MDR and HIV-TB, Sondalo, Italy; Department of Infection, Barts Health NHS Trust, London, UK.
¹¹ National Institute for Health Development, Tallinn, Estonia.
¹² Division of Clinical Infectious Diseases and German Center for Infection Research Tuberculosis Unit, Research Center Borstel, Borstel, Germany; Department of Medicine, University of Namibia School of Medicine, Windhoek, Namibia; Department of Medicine, Karolinska Institute, Stockholm, Sweden.

PMID: 26614196
DOI: 10.5588/ijtld.15.0274

Multicenter Study

Beyond multidrug-resistant tuberculosis in Europe: a TBNET study

G Günther et al. Int J Tuberc Lung Dis. 2015 Dec.

. 2015 Dec;19(12):1524-7.

doi: 10.5588/ijtld.15.0274.

Authors

G Günther¹, F van Leth², N Altet³, M Dedicoat⁴, R Duarte⁵, G Gualano⁶, H Kunst⁷, I Muylle⁸, V Spinu⁹, S Tiberi¹⁰, P Viiklepp¹¹, C Lange¹²; TBNET

Collaborators

Affiliations

¹ Division of Clinical Infectious Diseases and German Center for Infection Research Tuberculosis Unit, Research Center Borstel, Borstel, Germany; Department of Medicine, University of Namibia School of Medicine, Windhoek, Namibia.
² Department of Global Health, Academic Medical Center, University of Amsterdam and Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands.
³ Hospital Universitari Vall d'Hebron, Barcelona, Spain; Investigació i Recerca en Atenció Primària Jordi Gol, Barcelona, Spain.
⁴ Heart of England Foundation Trust, Birmingham, UK.
⁵ Centro Hospitalar de Vila Nova Gaia/Espinho, Vila Nova Gaia, Portugal; EpiUnit, Institute of Public Health, Medical School Porto University, Porto, Portugal.
⁶ L Spallanzani National Institute for Infectious Diseases, Rome, Italy.
⁷ Heart of England Foundation Trust, Birmingham, UK; Queen Mary University, London, UK.
⁸ St Pieter University Medical Centre, Brussels, Belgium.
⁹ Marius-Nasta-Institut, Bucharest, Romania.
¹⁰ Azienda Ospedaliera di Valtellina e Valchiavenna E Morelli Hospital, Reference Hospital for MDR and HIV-TB, Sondalo, Italy; Department of Infection, Barts Health NHS Trust, London, UK.
¹¹ National Institute for Health Development, Tallinn, Estonia.
¹² Division of Clinical Infectious Diseases and German Center for Infection Research Tuberculosis Unit, Research Center Borstel, Borstel, Germany; Department of Medicine, University of Namibia School of Medicine, Windhoek, Namibia; Department of Medicine, Karolinska Institute, Stockholm, Sweden.

PMID: 26614196
DOI: 10.5588/ijtld.15.0274

Abstract

The emergence of drug-resistant tuberculosis (TB) is a challenge to TB control in Europe. We evaluated second-line drug susceptibility testing in Mycobacterium tuberculosis isolates from patients with multidrug-resistant, pre-extensively drug-resistant (pre-XDR-TB) and XDR-TB at 23 TBNET sites in 16 European countries. Over 30% of bacilli from patients with pre-XDR-TB showed resistance to any fluoroquinolone and almost 70% to any second-line injectable drug. Respectively >90% and >80% of the XDR-TB strains tested showed phenotypic resistance to pyrazinamide and ethambutol. Resistance to prothionamide/ethionamide was high in bacilli from pre-XDR-TB patients (43%) and XDR-TB patients (49%).

PubMed Disclaimer

Cited by

Resistance to Second-Line Anti-TB Drugs in Cambodia: A Phenotypic and Genetic Study.
Cheng S, Hide M, Pheng SH, Kerléguer A, Delvallez G, Sam S, Mao TE, Nguyen TVA, Bañuls AL. Cheng S, et al. Infect Drug Resist. 2021 Mar 17;14:1089-1104. doi: 10.2147/IDR.S289907. eCollection 2021. Infect Drug Resist. 2021. PMID: 33762833 Free PMC article.
Predictors of time to unfavorable treatment outcomes among patients with multidrug resistant tuberculosis in Oromia region, Ethiopia.
Woldeyohannes D, Assefa T, Aman R, Tekalegn Y, Hailemariam Z. Woldeyohannes D, et al. PLoS One. 2019 Oct 30;14(10):e0224025. doi: 10.1371/journal.pone.0224025. eCollection 2019. PLoS One. 2019. PMID: 31665154 Free PMC article.
What Is Resistance? Impact of Phenotypic versus Molecular Drug Resistance Testing on Therapy for Multi- and Extensively Drug-Resistant Tuberculosis.
Heyckendorf J, Andres S, Köser CU, Olaru ID, Schön T, Sturegård E, Beckert P, Schleusener V, Kohl TA, Hillemann D, Moradigaravand D, Parkhill J, Peacock SJ, Niemann S, Lange C, Merker M. Heyckendorf J, et al. Antimicrob Agents Chemother. 2018 Jan 25;62(2):e01550-17. doi: 10.1128/AAC.01550-17. Print 2018 Feb. Antimicrob Agents Chemother. 2018. PMID: 29133554 Free PMC article.
Management of MDR-TB in HIV co-infected patients in Eastern Europe: Results from the TB:HIV study.
Efsen AMW, Schultze A, Miller RF, Panteleev A, Skrahin A, Podlekareva DN, Miro JM, Girardi E, Furrer H, Losso MH, Toibaro J, Caylà JA, Mocroft A, Lundgren JD, Post FA, Kirk O; TB: HIV study in EuroCoord. Efsen AMW, et al. J Infect. 2018 Jan;76(1):44-54. doi: 10.1016/j.jinf.2017.10.007. Epub 2017 Oct 20. J Infect. 2018. PMID: 29061336 Free PMC article.
Pyrazinamide resistance-conferring mutations in pncA and the transmission of multidrug resistant TB in Georgia.
Sengstake S, Bergval IL, Schuitema AR, de Beer JL, Phelan J, de Zwaan R, Clark TG, van Soolingen D, Anthony RM. Sengstake S, et al. BMC Infect Dis. 2017 Jul 12;17(1):491. doi: 10.1186/s12879-017-2594-3. BMC Infect Dis. 2017. PMID: 28697808 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ingenta plc

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Beyond multidrug-resistant tuberculosis in Europe: a TBNET study

Collaborators

Affiliations

Beyond multidrug-resistant tuberculosis in Europe: a TBNET study

Authors

Collaborators

Affiliations

Abstract

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Abstract

Similar articles

Cited by

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources